Agios Pharma (AGIO) Reports Phase 1 Data from Dose Expansion Cohort of Ivosidenib (AG-120)
Tweet Send to a Friend
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) today presented updated data from the dose expansion cohort of the Phase 1 study evaluating ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
